Roldac Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.80 M
- Revenue Growth 2105.43%
- Profit Growth 126.27%
- Ebitda -449.44%
- Net Worth 4.14%
- Total Assets 35.31%
About Roldac Pharmaceuticals
Roldac Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 December 2020 (Four years and two months 13 days old ). Its registered office is in Dehradun, Uttarakhand, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹0.80 M.
Soniya Rathore and Ravinder Rathore serve as directors at the Company.
Company Details
-
Location
Dehradun, Uttarakhand, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24290UR2020PTC011831
-
Company No.
011831
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Dec 2020
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Uttarakhand
Industry
Who are the key members and board of directors at Roldac Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Soniya Rathore
|
Director | 04-Dec-2020 | Current |
|
Ravinder Rathore
|
Director | 04-Dec-2020 | Current |
Financial Performance of Roldac Pharmaceuticals.
Roldac Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 2105.43% increase. The company also saw a substantial improvement in profitability, with a 126.27% increase in profit. The company's net worth moved up by a moderate rise of 4.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Roldac Pharmaceuticals?
Unlock access to Roldac Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.80 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Dec 2020 | Others | ₹0.80 M | Open |
How Many Employees Work at Roldac Pharmaceuticals?
Roldac Pharmaceuticals has a workforce of 0 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Roldac Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Roldac Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.